Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 23, 2007, Pages 6525-6528

  Galatsis, Paul ^a   Yamagata, Koji ^a   Wendt, John A ^a   Connolly, Cleo J ^a   Mickelson, John W ^a   Milbank, Jared B J ^a   Bove, Susan E ^a   Knauer, Christopher S ^a   Brooker, Rachel M ^a   Augelli Szafran, Corinne E ^a   Schwarz, Roy D ^a   Kinsora, Jack J ^a   Kilgore, Kenneth S ^a  

^a PFIZER INC   (United States)

Author keywords

1,5 Naphthyridine; 1,6 Naphthyridine; 1,8 Naphthyridine; Antagonist; mGlu5 receptor; Osteoarthritis; Pain; Rat

Indexed keywords

1,8 NAPHTHYRIDINE DERIVATIVE; 7 (1,6 NAPHTHYDRINE); NAPHTHYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; NAPHTHYRIDINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 35648935910     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.083     Document Type: Article

References (24)

1. Bach P., Isaac M., and Slassi A. Expert Opin. Ther. Patents 17 (2007) 371
2. Augelli-Szafran C., and Schwarz R. Ann. Rep. Med. Chem. 38 (2003) 21
3. Bach P., Nilsson K., Wallberg A., Bauer U., Hammerland L.G., Peterson A., Svensson T., Oesterlund K., Karis D., Boije M., and Wensbo D. Bioorg. Med. Chem. Lett. 16 (2006) 4792
4. Bach P., Nilsson K., Svensson T., Bauer U., Hammerland L.G., Peterson A., Wallberg A., Oesterlund K., Karis D., Boije M., and Wensbo D. Bioorg. Med. Chem. Lett. 16 (2006) 4788
5. Chua P.C., Nagasawa J.Y., Bleicher L.S., Munoz B., Schweiger E.J., Tehrani L., Anderson J.J., Cramer M., Chung J., Green M.D., King C.D., Reyes-Manalo G., and Cosford N.D.P. Bioorg. Med. Chem. Lett. 15 (2005) 4589
6. Iso Y., Grajkowska E., Wroblewski J.T., Davis J., Goeders N.E., Johnson K.M., Sanker S., Roth B.L., Tueckmantel W., and Kozikowski A.P. J. Med. Chem. 49 (2006) 1080
7. Alagille D., Baldwin R.M., Roth B.L., Wroblewski J.T., Grajkowska E., and Tamagnan G.D. Bioorg. Med. Chem. Lett. 15 (2005) 945
8. Alagille D., Baldwin R.M., Roth B.L., Wroblewski J.T., Grajkowska E., and Tamagnan G.D. Bioorg. Med. Chem. 13 (2004) 197
9. Jaechke G., Porter R., Buettelmann B., Ceccarelli S., Guba W., Kuhn B., Kolczewski S., Huwyler J., Mutel V., Peters J.-U., Ballard T., Prinssen E., Vieira E., Wichmann J., and Spooren W. Bioorg. Med. Chem. Lett. 17 (2007) 1307
10. Hammerland L., Johansson M., Malmstroem J., Mattsson J., Minidis A., Nilsson K., Peterson A., Wensbo D., Wallberg A., and Oesterlund K. Bioorg. Med. Chem. Lett. 16 (2006) 2467
11. Tasler S., Kraus J., Pegoraro S., Aschenbrenner A., Poggesi E., Testa R., Motta G., and Leonardi A. Bioorg. Med. Chem. Lett. 15 (2005) 2876
12. Bonnefous C., Vernier J.-M., Hutchinson J., Chung J., Reyes-Manalo G., and Kamenecka T. Bioorg. Med. Chem. Lett. 15 (2005) 1197
13. Kulkarni S., and Hauck Newman A. Bioorg. Med. Chem. 17 (2007) 2987
14. Milbank J., Knauer C., Augelli-Szafran C., Sakkab-Tan A., Lin K., Yamagata K., Hoffman J., Zhuang N., Thomas J., Galatsis P., Wendt J., Mickelson J., Schwarz R., Kinsora J., Lotarski S., Stakich K., Gillespie K., Lam W., and Mutlib M. Bioorg. Med. Chem. Lett. 17(16) (2007)
15. Wendt J., Deeter S., Bove S., Knauer C., Brooker R., Augelli-Szafran C., Schwartz R., Kinsora J., and Kilgore K. Bioorg. Med. Chem. Lett. 17 (2007) 5396
16. Reddy K.V., Mogilaiah K., and Sreenivasulu B. J. Indian Chem. Soc. 63 (1986) 443
17. Piao M.-Z., and Imafuku K. J. Heterocycl. Chem. 33 (1996) 389
18. Roesch R., and Larock R. J. Org. Chem. 67 (2002) 86
19. 2, 4 equiv TEA, 0.04 equiv CuI, 50 °C), followed by removal of TMS group (0.1 M NaOH in THF).
20. 2/EtOAc, 8:2) to afford 3-bromo-1.5-naphthyridine 11 (44 g, 35.8%) as a white solid.
21. The aryl boronic acids were either commercially available or synthesized between dipinacolatoborane and an aryl halide under standard Suzuki type conditions.
22. Piao M.-Z., and Imafuku K. J. Heterocycl. Chem. 33 (1996) 389
23. Bove S., Calcaterra S., Brooker R., Huber C., Guzman R., Juneau P., Schrier D., and Kilgore K. Osteoarthritis Cartilage 11 (2003) 821
24. All experimental procedures were conducted in an AAALAC International-accredited facility in compliance with the United States Department of Agriculture Animal Welfare Act Regulations and the Guide for the Care and Use of Laboratory Animals and were approved by the PGRD Ann Arbor Institutional Animal Care and Use Committee prior to initiation of the studies.